Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Progress in the fight against brain cancer.

[No authors listed]

Nature. 2019 Jan;565(7738):134. doi: 10.1038/d41586-019-00077-1. No abstract available.

PMID:
30626956
2.

Immune cells track hard-to-target brain tumours.

Zaidi N, Jaffee EM.

Nature. 2019 Jan;565(7738):170-171. doi: 10.1038/d41586-018-07728-9. No abstract available.

PMID:
30622348
3.

Targeting EGFRvIII for glioblastoma multiforme.

Yang J, Yan J, Liu B.

Cancer Lett. 2017 Sep 10;403:224-230. doi: 10.1016/j.canlet.2017.06.024. Epub 2017 Jun 23. Review.

PMID:
28649003
4.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

5.

Perspectives for immunotherapy in glioblastoma treatment.

Finocchiaro G, Pellegatta S.

Curr Opin Oncol. 2014 Nov;26(6):608-14. doi: 10.1097/CCO.0000000000000135. Review.

PMID:
25210870
6.

Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate.

Prins RM, Cloughesy TF, Liau LM.

N Engl J Med. 2008 Jul 31;359(5):539-41. doi: 10.1056/NEJMc0804818. No abstract available.

7.

The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Paff M, Alexandru-Abrams D, Hsu FP, Bota DA.

Hum Vaccin Immunother. 2014;10(11):3322-31. doi: 10.4161/21645515.2014.983002. Review.

8.

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.

Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW.

Clin Cancer Res. 2016 Oct 1;22(19):4776-4785. Epub 2016 May 25.

9.

Effective immunotherapy of rat glioblastoma with prolonged intratumoral delivery of exogenous heat shock protein Hsp70.

Shevtsov MA, Pozdnyakov AV, Mikhrina AL, Yakovleva LY, Nikolaev BP, Dobrodumov AV, Komarova EY, Meshalkina DA, Ischenko AM, Pitkin E, Guzhova IV, Margulis BA.

Int J Cancer. 2014 Nov 1;135(9):2118-28. doi: 10.1002/ijc.28858. Epub 2014 Apr 1.

10.

Glioma antigen.

Toda M.

Adv Exp Med Biol. 2012;746:77-84. doi: 10.1007/978-1-4614-3146-6_6. Review.

PMID:
22639160
11.

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH.

Neuro Oncol. 2008 Feb;10(1):98-103. Epub 2007 Dec 13.

12.

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.

Wheeler CJ, Das A, Liu G, Yu JS, Black KL.

Clin Cancer Res. 2004 Aug 15;10(16):5316-26.

13.

Vaccination in the immunotherapy of glioblastoma.

Kong Z, Wang Y, Ma W.

Hum Vaccin Immunother. 2018 Feb 1;14(2):255-268. doi: 10.1080/21645515.2017.1388481. Epub 2017 Dec 11. Review.

14.

Immunotherapy with tumor vaccines for the treatment of malignant gliomas.

Ajay D, Sanchez-Perez L, Choi BD, De Leon G, Sampson JH.

Curr Drug Discov Technol. 2012 Dec;9(4):237-55. Review.

PMID:
22339070
15.
16.

Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.

Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT.

Clin Cancer Res. 2013 Jan 1;19(1):205-14. doi: 10.1158/1078-0432.CCR-11-3358. Epub 2012 Aug 7.

17.

Dendritic cell vaccines to combat glioblastoma.

Wheeler CJ.

Expert Rev Neurother. 2010 Apr;10(4):483-6. doi: 10.1586/ern.10.26. No abstract available.

PMID:
20367199
18.

Use of Chimeric Antigen Receptor T Cells as a Potential Therapeutic for Glioblastoma.

Babar Khan M, Chakraborty S, Boockvar JA.

Neurosurgery. 2017 May 1;80(5):N33-N34. doi: 10.1093/neuros/nyx105. No abstract available.

PMID:
28586488
19.

Progress in active-specific immunotherapy of brain malignancies.

Tjoa BA, Salgaller ML.

Expert Opin Investig Drugs. 2000 Sep;9(9):2093-101. Review.

PMID:
11060795
20.

New weapons against brain tumors. Emerging techniques from multi-national research curb the growth of brain tumors.

[No authors listed]

Duke Med Health News. 2007 Oct;13(10):5. No abstract available.

PMID:
18277427

Supplemental Content

Support Center